{"id":113365,"date":"2026-06-10T16:28:07","date_gmt":"2026-06-10T10:58:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=113365"},"modified":"2026-06-10T16:28:09","modified_gmt":"2026-06-10T10:58:09","slug":"concord-biotech-share-price-usfda-tofacitinib","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/","title":{"rendered":"Concord Biotech Share Price Surges Up to 5.96% After USFDA Approves Tofacitinib Tablets ANDA in 5 mg and 10 mg Strengths"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Concord Biotech share price: CMP Rs 1,340 (+5.33%) on June 10, 2026. Open Rs 1,284, High Rs 1,349.90, Low Rs 1,282.60, Prev close Rs 1,272.20. USFDA ANDA approval for Tofacitinib Tablets 5mg and 10mg. US market: ~$500 million. 52W high Rs 2,150.40 (Jun 11, 2025); 52W low Rs 987 (Apr 2, 2026). MCap Rs 13,848 crore.<\/em><\/p>\n<p>The <strong><a href=\"https:\/\/univest.in\/user\/stocks\/concordbio\/concord-biotech-ltd-share-price-today\">Concord Biotech<\/a> share price<\/strong> surged up to 5.33% to Rs 1,340, hitting an intraday high of Rs 1,349.90 on Wednesday, June 10, 2026, after the Ahmedabad-based biopharmaceutical company announced receipt of US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. The approval was disclosed through a stock exchange filing under SEBI Regulation 30. The combined US market for Tofacitinib Tablets across both strengths is estimated at approximately US$500 million, opening a significant revenue opportunity for the <strong>Concord Biotech share price<\/strong> and its US generics business. This marks the company&#8217;s second major USFDA ANDA approval within a week, following the Mycophenolate Mofetil approval on June 3, 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=concord-biotech-share-price\"><strong>Click Here &#8211; Get Free Stock Research From Univest<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#USFDA_Tofacitinib_Approval_Key_Details\" title=\"USFDA Tofacitinib Approval: Key Details\">USFDA Tofacitinib Approval: Key Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#Concord_Biotech_Share_Price_Current_Snapshot\" title=\"Concord Biotech Share Price: Current Snapshot\">Concord Biotech Share Price: Current Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#Why_Tofacitinib_is_a_Significant_Opportunity\" title=\"Why Tofacitinib is a Significant Opportunity\">Why Tofacitinib is a Significant Opportunity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#Recent_USFDA_Approval_Track_Record\" title=\"Recent USFDA Approval Track Record\">Recent USFDA Approval Track Record<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#Technical_Position_37_Below_52-Week_High\" title=\"Technical Position: 37% Below 52-Week High\">Technical Position: 37% Below 52-Week High<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#Why_is_Concord_Biotech_share_price_rising_today\" title=\"Why is Concord Biotech share price rising today?\">Why is Concord Biotech share price rising today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#What_is_Tofacitinib_and_why_is_the_USFDA_approval_significant\" title=\"What is Tofacitinib and why is the USFDA approval significant?\">What is Tofacitinib and why is the USFDA approval significant?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#What_is_the_Concord_Biotech_share_price_outlook_after_the_USFDA_approval\" title=\"What is the Concord Biotech share price outlook after the USFDA approval?\">What is the Concord Biotech share price outlook after the USFDA approval?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/concord-biotech-share-price-usfda-tofacitinib\/#What_does_Concord_Biotech_do_as_a_company\" title=\"What does Concord Biotech do as a company?\">What does Concord Biotech do as a company?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"USFDA_Tofacitinib_Approval_Key_Details\"><\/span><strong>USFDA Tofacitinib Approval: Key Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr>\n<th style=\"border: 1px solid #000; padding: 7px 9px; background: #000; color: #fff; text-align: left;\">Detail<\/th>\n<th style=\"border: 1px solid #000; padding: 7px 9px; background: #000; color: #fff; text-align: left;\">Information<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Type of Approval<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">USFDA Abbreviated New Drug Application (ANDA) &#8212; Final Approval<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Drug<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Tofacitinib Tablets<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Strengths Approved<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">5 mg and 10 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">US Market Size (both strengths)<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">~US$500 million (source: IQVIA estimates)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Indications<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rheumatoid arthritis (RA), Psoriatic arthritis, Ankylosing spondylitis, Ulcerative colitis, Juvenile idiopathic arthritis<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Regulatory Filing<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">SEBI Regulation 30 disclosure, June 10, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Branded Reference Drug<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Xeljanz (Pfizer) &#8212; patent expiry opens generic opportunity<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Previous USFDA Approvals (FY26)<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Mycophenolate Mofetil (June 3, 2026), Teriflunomide Tablets (April 2025)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 22px 26px 18px; margin: 24px 0; cursor: pointer;\">\n<p style=\"font-size: 18px; font-weight: bold; color: #0a0a23; margin: 0 0 8px;\">Research Pharma Stocks and Concord Biotech With Univest<\/p>\n<p style=\"font-size: 14px; color: #3a3a5c; margin: 0 0 10px;\">Univest covers Concord Biotech and all pharma stocks with live prices, USFDA tracker, and analyst research.<\/p>\n<ul style=\"margin: 0 0 12px 18px; color: #3a3a5c; font-size: 14px; line-height: 1.8;\">\n<li>Live Concord Biotech share price tracking and USFDA approval alerts<\/li>\n<li>Pharma sector analysis with ANDA pipeline and US market opportunity data<\/li>\n<li>Daily stock picks with expert research from Univest analysts<\/li>\n<\/ul>\n<p style=\"font-size: 14px; color: #3a3a5c; margin: 0 0 12px;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\">Top Stock Picks<\/a> on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 14px; font-weight: 600; padding: 10px 22px; border-radius: 50px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Concord_Biotech_Share_Price_Current_Snapshot\"><\/span><strong>Concord Biotech Share Price: Current Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr>\n<th style=\"border: 1px solid #000; padding: 7px 9px; background: #000; color: #fff; text-align: left;\">Parameter<\/th>\n<th style=\"border: 1px solid #000; padding: 7px 9px; background: #000; color: #fff; text-align: left;\">Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">NSE Symbol<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">CONCORDBIO<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Sector<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Pharmaceuticals \/ Biopharma<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">CMP (Jun 10, intraday high)<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rs 1,340 (+5.33%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">At 10:51 AM<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rs 1,349.90 (day high)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Previous Close<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rs 1,272.20<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Day High<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rs 1,349.90<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">52-Week High<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rs 2,150.40 (June 11, 2025)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">52-Week Low<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rs 987 (April 2, 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">YTD Performance<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">-1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">1-Month Return<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">+13%<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">1-Week Return<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">+10%<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Market Capitalisation<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Rs 13,848.05 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">Business<\/td>\n<td style=\"border: 1px solid #000; padding: 7px 9px; background: #fff; color: #000;\">R&amp;D-driven biopharma: APIs (fermentation) + finished formulations<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Tofacitinib_is_a_Significant_Opportunity\"><\/span><strong>Why Tofacitinib is a Significant Opportunity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Concord Biotech share price<\/strong> rally reflects the market&#8217;s recognition of the Tofacitinib opportunity. Tofacitinib is a JAK (Janus Kinase) inhibitor that has become a significant drug class in treating autoimmune conditions. The branded version, Xeljanz (Pfizer), generated peak annual US revenues exceeding $1 billion before patent expiry. With the combined 5 mg and 10 mg US market estimated at $500 million, and with Concord now holding a final ANDA approval, the company can file for a supply authorisation and begin commercial launch in the US once it clears any remaining regulatory steps. This direct-to-market access in regulated pharmacy channels is a meaningful step forward for the <strong>Concord Biotech share price<\/strong>&#8216;s revenue trajectory.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_USFDA_Approval_Track_Record\"><\/span><strong>Recent USFDA Approval Track Record<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Concord Biotech share price<\/strong> has been building strong momentum from a series of USFDA approvals in FY26. On June 3, 2026, the company received USFDA approval for Mycophenolate Mofetil for Oral Suspension USP (200 mg\/ml), targeting the US$30 million oral suspension market, and the stock had surged 8% on that day. Prior to that, in April 2025, the company received approval for Teriflunomide Tablets (7 mg and 14 mg), targeting a ~$402 million US market. Each approval adds a new revenue stream to the US business, compounding the growth potential visible in the <strong>Concord Biotech share price<\/strong>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Position_37_Below_52-Week_High\"><\/span><strong>Technical Position: 37% Below 52-Week High<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Despite today&#8217;s strong surge, the <strong>Concord Biotech share price<\/strong> at Rs 1,327-1,348 remains approximately 37-40% below its 52-week high of Rs 2,150.40 (hit on June 11, 2025). The stock hit a 52-week low of Rs 987 on April 2, 2026, before recovering on successive USFDA approval catalysts. The recovery from Rs 987 to Rs 1,348 represents a 36.6% gain from the low, supported by the company&#8217;s strong regulatory execution. For the <strong>Concord Biotech share price<\/strong> to fully recover, sustained US launch momentum and revenue contribution from the newly approved products will be key.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen Concord Biotech and Top Pharma Stocks Live on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Concord Biotech share price<\/strong> surge of up to 5.96% (intraday high Rs 1,349.90, current Rs 1,336.20) today is directly attributed to the USFDA ANDA approval for Tofacitinib Tablets in 5 mg and 10 mg, addressing a ~$500 million US market. Combined with the Mycophenolate Mofetil approval a week ago, Concord Biotech is building a robust US generics pipeline that could drive sustained re-rating in the <strong>Concord Biotech share price<\/strong> over the next 12-24 months. Track live prices and USFDA approval news on Univest.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Concord Biotech share price live with pharma research and USFDA alerts on Univest.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data sourced from NSE\/BSE\/public filings. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776). Investments are subject to market risk. Consult a SEBI-registered financial advisor before investing.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Concord_Biotech_share_price_rising_today\"><\/span><strong>Why is Concord Biotech share price rising today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Concord Biotech share price is rising up to 5.96% today after the company announced receipt of USFDA final approval for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval opens a US$500 million market opportunity for the company. Tofacitinib is a JAK inhibitor used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The USFDA nod positions Concord Biotech to compete in the generic Tofacitinib market in the US, which is the world&#8217;s largest generics market.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Tofacitinib_and_why_is_the_USFDA_approval_significant\"><\/span><strong>What is Tofacitinib and why is the USFDA approval significant?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Tofacitinib is a Janus Kinase (JAK) inhibitor used to treat moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. The branded version is Xeljanz by Pfizer, which had annual US revenues exceeding $1 billion at peak. The combined US market for both 5 mg and 10 mg Tofacitinib Tablets is estimated at approximately US$500 million. Concord Biotech receiving USFDA ANDA approval allows it to market a generic version, capturing a share of this significant market.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Concord_Biotech_share_price_outlook_after_the_USFDA_approval\"><\/span><strong>What is the Concord Biotech share price outlook after the USFDA approval?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Concord Biotech share price at ~Rs 1,340 today is still approximately 37.7% below its 52-week high of Rs 2,150.40 (June 11, 2025), suggesting potential recovery room if the US generics launch gains traction. The company has been building a strong USFDA approval track record in FY26 with multiple ANDA clearances including Mycophenolate Mofetil and now Tofacitinib. Each approved product expands the US revenue pipeline. The 1-month return of +13% and 1-week return of +10% suggest the stock is in a positive momentum phase.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Concord_Biotech_do_as_a_company\"><\/span><strong>What does Concord Biotech do as a company?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Concord Biotech Limited, founded in 2000, is an R&amp;D-driven biopharmaceutical company headquartered in Ahmedabad. The company specialises in the production of Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Its API portfolio includes immunosuppressants, oncology, and anti-infective categories. The US generics market is a key growth vector, and the company has been progressively building its ANDA pipeline to capitalise on patent expiry opportunities. Concord Biotech incorporated a marketing subsidiary Concord Lifegen for US commercial activities.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why is Concord Biotech share price rising today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Concord Biotech share price is rising up to 5.96% today after the company announced receipt of USFDA final approval for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval opens a US$500 million market opportunity for the company. Tofacitinib is a JAK inhibitor used for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. The USFDA nod positions Concord Biotech to compete in the generic Tofacitinib market in the US, which is the world's largest generics market.\"}},{\"@type\":\"Question\",\"name\":\"What is Tofacitinib and why is the USFDA approval significant?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Tofacitinib is a Janus Kinase (JAK) inhibitor used to treat moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. The branded version is Xeljanz by Pfizer, which had annual US revenues exceeding $1 billion at peak. The combined US market for both 5 mg and 10 mg Tofacitinib Tablets is estimated at approximately US$500 million. Concord Biotech receiving USFDA ANDA approval allows it to market a generic version, capturing a share of this significant market.\"}},{\"@type\":\"Question\",\"name\":\"What is the Concord Biotech share price outlook after the USFDA approval?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Concord Biotech share price at ~Rs 1,340 today is still approximately 37.7% below its 52-week high of Rs 2,150.40 (June 11, 2025), suggesting potential recovery room if the US generics launch gains traction. The company has been building a strong USFDA approval track record in FY26 with multiple ANDA clearances including Mycophenolate Mofetil and now Tofacitinib. Each approved product expands the US revenue pipeline. The 1-month return of +13% and 1-week return of +10% suggest the stock is in a positive momentum phase.\"}},{\"@type\":\"Question\",\"name\":\"What does Concord Biotech do as a company?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Concord Biotech Limited, founded in 2000, is an R&D-driven biopharmaceutical company headquartered in Ahmedabad. The company specialises in the production of Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Its API portfolio includes immunosuppressants, oncology, and anti-infective categories. The US generics market is a key growth vector, and the company has been progressively building its ANDA pipeline to capitalise on patent expiry opportunities. Concord Biotech incorporated a marketing subsidiary Concord Lifegen for US commercial activities.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Concord Biotech share price surges up to 5.96% to Rs 1,348 on USFDA Tofacitinib ANDA approval. US market size $500 mn. 52W low Rs 987. Second USFDA approval this week. Full analysis.<\/p>\n","protected":false},"author":34,"featured_media":113398,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3857],"class_list":["post-113365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-share-price-surges"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1781089116:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["81"],"rank_math_title":["Concord Biotech Share Price Jumps 5.96% on USFDA Tofacitinib Nod"],"rank_math_description":["Concord Biotech share price surges up to 5.96% to Rs 1,348 on USFDA ANDA approval for Tofacitinib Tablets 5mg and 10mg. US market size $500 million. 52W low Rs 987. Analysis."],"rank_math_focus_keyword":["Concord Biotech Share Price"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["113398"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["16923"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Concord-Biotech-Share-Price-Surges.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/113365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=113365"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/113365\/revisions"}],"predecessor-version":[{"id":113404,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/113365\/revisions\/113404"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/113398"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=113365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=113365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=113365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}